A randomized, double-blind, placebo controlled, phase IIA study to assess the effect on GERD [gastro-esophageal reflux disease] symptoms, PK [pharmacokinetics], safety and tolerability of 4 weeks treatment with AZD3355 65 mg bid [twice daily] as add-on treatment to a PPI [proton pump inhibitor] in patients with an incomplete response to PPI

Trial Profile

A randomized, double-blind, placebo controlled, phase IIA study to assess the effect on GERD [gastro-esophageal reflux disease] symptoms, PK [pharmacokinetics], safety and tolerability of 4 weeks treatment with AZD3355 65 mg bid [twice daily] as add-on treatment to a PPI [proton pump inhibitor] in patients with an incomplete response to PPI

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2013

At a glance

  • Drugs Lesogaberan; Proton pump inhibitors
  • Indications Gastro-oesophageal reflux
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 18 May 2011 Actual end date (Jun 2007) added as reported by ClinicalTrials.gov.
    • 25 Nov 2009 Primary endpoint 'Clinical response' has been met.
    • 25 Nov 2009 Results reported at Gastro 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top